Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anticholesteremic agents in children].

Jean-Philippe Girardet1

  • 1Service de Gastro-Entérologie et de Nutrition Pédiatriques, Hôpital Armand-Trousseau, Paris, France. jean-philippe.girardet@trs.ap-hop-paris.fr

Therapie
|June 26, 2003
PubMed
Summary

Cholesterol-lowering drugs are recommended for children with genetic high cholesterol conditions if diet fails. Bile acid-binding resins are the first choice, with statins an option for older children.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Religious dietary rules and their potential nutritional and health consequences.

International journal of epidemiology·2020
Same author

Intermediate-Term Efficacy and Tolerance of Statins in Children.

The Journal of pediatrics·2019
Same author

Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France.

Journal of lipid research·2016
Same author

Erratum to: Review of the nutritional benefits and risks related to intense sweeteners.

Archives of public health = Archives belges de sante publique·2015
Same author

Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability.

Paediatric drugs·2011
Same author

Intractable diarrhea with tufting enteropathy: a favorable outcome is possible.

Journal of pediatric gastroenterology and nutrition·2011

Area of Science:

  • Pediatric Endocrinology
  • Cardiovascular Disease Prevention
  • Pharmacology

Context:

  • Hypercholesterolemia in children is a key factor in preventing adult-onset coronary heart disease.
  • Genetic dyslipidemias like familial hypercholesterolemia necessitate early intervention.
  • High LDL-cholesterol levels in children with genetic conditions pose significant cardiovascular risks.

Purpose:

  • To outline the appropriate use of cholesterol-lowering medications in pediatric patients.
  • To define treatment thresholds for pharmacotherapy in children with inherited hypercholesterolemia.
  • To review the safety and efficacy profiles of available drug classes for pediatric use.

Summary:

  • Pharmacological treatment for hypercholesterolemia in children is indicated for hereditary conditions when LDL-cholesterol remains above 190 mg/dL after 6 months of diet.
  • Bile acid-binding resins (colestyramine) are the primary choice due to established efficacy and safety in children.
  • HMG-CoA reductase inhibitors (statins) may be used in children over 8-9 years old if adherence to resins is poor, though long-term safety is not fully known.
  • Fibrates are effective but lack sufficient safety data from controlled pediatric studies.

Impact:

  • Provides guidance for clinicians on managing pediatric hypercholesterolemia.
  • Highlights the importance of early intervention for genetic lipid disorders.
  • Informs treatment decisions regarding the selection and sequencing of lipid-lowering therapies in children.

Related Experiment Videos